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ABSTRACT
Importance and aims The role of CT colonography
(CTC) as a colorectal cancer (CRC) screening test is
uncertain. The aim of our trial was to compare
participation and detection rate (DR) with sigmoidoscopy
(flexible sigmoidoscopy (FS)) and CTC in a screening
setting.
Design setting and participants We conducted
two randomised clinical trials (RCTs). (1) Participation
RCT: individuals, aged 58 years, living in Turin (Italy),
were randomly assigned to be invited to FS or CTC
screening; (2) detection RCT: residents in northern Italy,
aged 58–60, giving their consent to recruitment, were
randomly allocated to CTC or FS. Polyps ≥6 mm at CTC,
or ‘high-risk’ distal lesions at FS, were referred for
colonoscopy (TC).
Main outcome measures Participation rate
(proportion of invitees examined); DR of advanced
adenomas or CRC (advanced neoplasia (AN)).
Results Participation was 30.4% (298/980) for CTC
and 27.4% (267/976) for FS (relative risk (RR) 1.1; 95%
CI 0.98 to 1.29). Among men, participation was higher
with CTC than with FS (34.1% vs 26.5%, p=0.011). In
the detection RCT, 2673 subjects had FS and 2595 had
CTC: the AN DR was 4.8% (127/2673, including 9
CRCs) with FS and 5.1% (133/2595, including 10 CRCs)
with CTC (RR 1.08; 95% CI 0.85 to 1.37). Distal AN DR
was 3.9% (109/2673) with FS and 2.9% (76/2595)
with CTC (RR 0.72; 95% CI 0.54 to 0.96); proximal AN
DR was 1.2% (34/2595) for FS vs 2.7% (69/2595) for
CTC (RR 2.06; 95% CI 1.37 to 3.10).
Conclusions and relevance Participation and DR for
FS and CTC were comparable. AN DR was twice as high
in the proximal colon and lower in the distal colon with
CTC than with FS. Men were more likely to participate in
CTC screening.
Trial registration number NCT01739608; Pre-
results.
BACKGROUND
Colorectal cancer (CRC) is the third most com-
monly diagnosed cancer and the second cause of
death from cancer worldwide.1
Significance of this study
What is already known on this subject?
▸ Sigmoidoscopy has been shown to reduce
colorectal cancer (CRC) incidence and mortality
in population-based randomised trials.
▸ CT colonography (CTC) has been proposed as a
potential test for population-based screening
due to its high acceptability and ability to
image the entire colon.
▸ Comparative data of CTC performance in a
screening setting are available only from a
Dutch trial, using colonoscopy (TC) as a
comparator test, and showing that the higher
participation rate achievable with CTC may
compensate the lower detection rate of
advanced neoplasia compared with TC.
What are the new findings
▸ CTC and flexible sigmoidoscopy (FS), when
used as primary screening tests in a
population-based setting, show a comparable
performance, both in terms of participation and
of advanced neoplasia yield.
▸ Sigmoidoscopy appeared to compensate the
expected lower diagnostic yield in the proximal
colon with a higher detection rate in the distal
part.
▸ Participation was higher among men invited for
CTC screening than among those invited for FS
screening, while no difference could be
observed among women.
How might it impact on clinical practice in
the foreseeable future?
▸ CTC shows equivalent diagnostic performance
and acceptability as endoscopic tests.
Comparative cost-effectiveness data are needed
to assess the possible role of CTC in a
screening setting, also considering the impact
of different management strategies for
extra-colonic findings.
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Once-only flexible sigmoidoscopy (FS) reduces CRC inci-
dence and mortality, especially in the distal colon.2–5 Thus, its
use as a primary screening test is recommended, and FS-based
organised population programmes are ongoing.6
Head-to-head screening studies with colonoscopy have shown
that CT colonography (CTC) is a marginally invasive imaging
test that accurately detects advanced neoplasia (AN).7–10 In a
randomised setting, CTC showed a higher participation rate
than colonoscopy and a similar diagnostic yield for AN.11
Similarly to FS, CTC does not require sedation and cathartic
preparation.12 13 In addition, CTC systematically explores the
proximal colon, which is beyond reach of FS. Computer-aided
detection (CAD) when using a first-reader paradigm may further
enhance the capabilities of CTC by reducing its reporting time
while ensuring high diagnostic accuracy.14–16
No direct comparison between CTC and FS is available to
date. To bridge this knowledge gap we have undertaken a study
aimed at comparing AN detection rate (DR) and participation
rate of non-cathartic CTC and FS in average risk individuals
aged 58–60 years in the context of a population-based screening
programme.
METHODS
Study design and participants
The study design and rationale have been described in detail in
a previous publication and are available online.14 To reduce a
possible source of bias, related to self-selection of subjects at dif-
ferent baseline risk for CRC to different screening protocols,
this study included two separate randomised clinical trials
(RCTs): (1) a pragmatic RCT (proteus 1) comparing participa-
tion among eligible people living in Turin, who were randomly
allocated to be invited for CRC screening by CTC or FS; (2) an
efficacy RCT (proteus 2) comparing detection of AN (advanced
adenoma+CRC) of CTC and FS among volunteers, conducted
in all sites. The two RCTs differed in their recruiting and ran-
domisation procedures.
The target population included 58 year old residents in the
Piedmont Region (three screening centres involved with six clin-
ical sites) and 60 year old residents of the city of Verona (two
clinical sites involved), eligible for invitation in their respective
population-based screening programmes between October 2010
and December 2013. General practitioners (GPs) were asked to
exclude individuals if they had a family (more than one first-
degree relative) or personal history of CRC/polyps; if they had a
history of IBD; if they had undergone colonoscopy in the previ-
ous 5 years or a faecal occult blood test (FOBT) in the previous
2 years; those diagnosed with a terminal illness.
Approval of the study was obtained by the local ethics
review committees of all participating clinical sites. All indivi-
duals gave informed written consent. Screening-related assess-
ments were offered free of charge to all subjects attending the
invitation.
Randomisation and invitation procedures
For both the RCTs, the randomisation scheme was computer
generated within the information technology screening system
which also manages screening invitations and appointments as
described elsewhere.14
Participation trial: proteus 1
All individuals eligible for invitation in Turin in September 2012
and in January 2013 were randomly allocated (ratio: 1:1) to FS
or CTC. Subjects were mailed a personal letter, signed by their
GP, offering a pre-fixed appointment to one of the tests, based
on the outcome of randomisation. The letter included a leaflet
that concisely described the screening procedure and its possible
side effects. Subjects were asked to call the screening centre to
confirm, modify, or cancel their appointment. A reminder letter
was mailed to all subjects who did not respond to the initial
invitation within 45 days.
Detection trial: proteus 2
Eligible individuals from Piedmont and Verona screening pro-
grammes were sent an invitation letter to participate in the trial.
The letter included a leaflet that outlined the trial objectives,
described the screening tests, their advantages and possible
risks. The mailing specified that participation in the trial
entailed the consent to be randomised to receive one of the two
screening tests. If interested, invitees were asked to call the
screening centre to give their consent to be recruited.
Responders giving their consent to enter the study were ran-
domly allocated either to FS or CTC and offered the appoint-
ment for the assigned test. Individuals refusing randomisation
and non-responders were invited after 1 month to FS according
to the regional screening protocol.
Screening procedures
Flexible sigmoidoscopy
Bowel preparation consisted of a single enema (133 mL of 22%
sodium phosphate) self-administered at home 2 h before the
test. A standard scope was advanced beyond the sigmoid-
descending colon junction without sedation. Polyps <10 mm
detected during FS were immediately removed and sent for
histologic evaluation. Subjects with polyps ≥10 mm, or with
‘high risk’ polyps (at least one advanced adenoma <10 mm, or
more than two small tubular adenomas with low-grade dyspla-
sia) were referred for colonoscopy (see section ‘Assessment col-
onoscopy’); those with polyps too large to be removed or with
suspected CRCs were referred for surgery; those with a negative
FS or with low-risk polyps were discharged. Screenees were
invited to repeat the test at a later date if preparation was
inadequate.
CT colonography
Non-cathartic CTC preparation and exam technique are
described in detail elsewhere14 (see also online supplementary
appendix). Briefly, screenees were instructed to follow a low-
residue diet and to intake a sachet of stool softener at the three
main meals starting 3 days before the examination date. Faecal
tagging was obtained by oral administration of an iodine solu-
tion starting 2 h before the examination. Following automatic
insufflation of carbon dioxide, supine and prone scans were
obtained using a low-dose scanning protocol. Intravenous con-
trast medium was not administered; n-butyl-scopolamine was
administered according to the common practice in each partici-
pating centre. Radiographers and nurses participating in the
study followed a one-day course on exam technique and quality
assurance.
In Piedmont, CTC exams were transferred through a regional
ICT network to a centralised reading centre for interpretation.
In Verona, CTC interpretation was performed in the two local
hospitals participating in the study. CTC data were interpreted
on a commercial workstation (CAD-COLON software V.1.20,
im3D, Turin, Italy),14 using a previously validated CAD reading
paradigm.14–16 CAD reading consisted of the evaluation of the
list of CAD prompts, followed by a fast two-dimensional review
(see also online supplementary appendix). Participants with
inadequate CTC because of poor bowel preparation, poor
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distension or artefacts were invited by telephone to undergo FS.
Participants with lesions ≥6 mm were contacted by phone to
arrange colonoscopy. Participants with negative results (no
colonic lesions or polyps <6 mm) were informed by regular
mail. Extra-colonic findings (ECFs) were assessed using a stand-
ard soft-tissue window. Cases with E4 findings, according to
C-RAD classification,17 or with aortic aneurysms ≥4 cm were
invited to undergo additional testing. ECFs known prior to
CTC were excluded from further assessments (see also online
supplementary appendix).
All radiologists participating in the trial had reported at least
300 colonoscopy-verified CTC examinations; in addition they
were required to attend a 3-day hands-on CTC screening course
and to obtain a per-patient sensitivity and specificity of at least
90% during a final examination, which consists of interpreting
30 screening cases. Radiographers and nurses attended a course
aimed to introduce and explain the study procedures, and to
discuss specific requirements related to the examination proce-
dures, or patient’s counselling, within the study. No formal
assessment was planned at the end of the training.
Assessment colonoscopy
Colonoscopy was performed using standard high-definition
endoscopes following a cathartic bowel preparation.14 The exam
was considered complete if the caecum was visualised or, in the
case of failure, when a subsequent colonoscopy, performed
within 6 months after the index one, reached the caecum; the
combined results of the two exams were considered for analysis.
All detected lesions were measured with open biopsy forceps
and annotated according to size, morphology and localisation.
Histology was defined according to WHO criteria.18
Advanced adenoma was defined as an adenoma with any of the
following features: size of at least 10 mm, high-grade dysplasia,
or villous component >20%. Cancer was defined as the inva-
sion of malignant cells beyond the muscularis mucosae.
Adverse events of screening tests
Adverse events of CTC, FS and colonoscopy were recorded at
the time of procedures. All participants were instructed to
contact the primary investigator if adverse events occurred
within 2 weeks of the procedures.
Statistical analysis
Primary outcomes were participation rate to the screening invi-
tation and DR for AN (ie, CRC and advanced adenomas).
Participation rate was defined as the number of participants
undergoing the screening test relative to the total number of
invitees. The DR for AN was defined as the proportion of parti-
cipants with AN over the total number of participants.
Differences were expressed as relative risk with 95% CIs.
Multivariable estimation of prevalence ratios were obtained
using log-binomial regression; adjustments were made for age,
gender, family history (one first-degree relative with CRC) and
screening programme, to allow for variability in adenoma and
CRC DRs. We also estimated the prevalence of advanced neo-
plasms by colonic location (rectum-sigmoid colon vs proximal
colon, from descending colon to caecum) in the two arms. All
statistical tests were two sided and were considered statistically
significant at p<0.05.
The SAS statistical software (V.9.1) was used for the analysis.
Sample size
Assuming 25% participation in FS screening,6 19 1000 invitees
per group would allow 80% power to detect as statistically
significant an absolute increase in CTC participation rate >5%,
with a 0.05 significance level. The overall AN prevalence at FS
was assumed to be 5%.6 19 Assuming a similar increase in the
AN yield with CTC as with TC,19 a sample size of 2500 partici-
pants per group could allow 80% power to be achieved to
detect as statistically significant the expected 2% absolute
increase in AN prevalence between screening groups, with a
0.05 significance level for the two-sided test.
RESULTS
Participation trial: proteus 1
The flow diagram on the left in figure 1 summarises the results
of the participation trial. The overall participation rate was
30.4% (298/980) for CTC and 27.0% (264/976) for FS (RR
1.12; 95% CI 0.98 to 1.29). Participation rates for CTC and FS
did not differ among women (26.7% vs 27.6%; RR 0.98; 95%
CI 0.79 to 1.20), while men showed a higher participation to
CTC screening (34.1% vs 26.5%; RR 1.3; 95% CI 1.07 to
1.65; p=0.011).
Detection trial: proteus 2
The trial flow for AN detection is also described in figure 1.
The final analysis included 2673 subjects allocated to the FS
and 2595 to the CTC group (table 1).
The screening examination was judged inadequate in 79
(3.0%) cases in the CTC group and in 65 (2.4%) in the FS group.
The reasons for non-diagnostic CTC were inadequate faecal
tagging in 69% (55/79) of cases, poor bowel preparation in 23%
(18/79) and insufficient distension in 8% (6/79); poor bowel
preparation was mentioned as the reason for non-diagnostic
exam in all cases in the FS arm. Among the 271 participants
(10.1%) referred to colonoscopy in the FS group, compliance to
colonoscopy was 87% (235/271) and the caecum was reached in
96% of cases (225/235); in the CTC group, 264 (10.2%) were
referred for colonoscopy; 260 (99%) performed the exam with a
completion rate of 94% (n=244).
The AN DR was 5.1% (n=133, including 10 CRCs) in the
CTC arm compared with 4.7% (n=127, including 9 CRCs) in
the FS arm (RR 1.1; 95% CI 0.9 to 1.4; p=0.524). Per-patient
DR, by gender and size of the most advanced lesion, is reported
in table 2. Male gender emerged as an independent predictor of
AN risk in the multivariable analysis, also adjusted for screening
arm and trial centre (table 3).
The distribution of AN detected by the two tests showed a
different pattern by colonic site (table 4). The prevalence of AN
in the distal colon was 4.1% (109) for FS versus 2.9% (76) for
CTC (RR 0.72; 95% CI 0.54 to 0.96), while the prevalence of
AN in the proximal colon was 2.7% (69) for CTC vs 1.3% (34)
for FS (RR 2.06; 95% CI 1.37 to 3.10). Isolated AN in the
proximal colon was present in 57 (2.2%) and 18 (0.7%) CTC
and FS participants, respectively. In the CTC group, men were
at higher risk of having proximal advanced disease than women
(CTC: RR 2.1; 95% CI 1.3 to 3.2).
Histology of detected adenomas according to size is reported
in table 5. Out of 560 adenomas detected among FS partici-
pants, 117 (20.8%) were at least 10 mm in size, 93 (16.6%) had
a villous component >20% and 42 (7.5%) contained high-grade
dysplasia. Out of 408 adenomas detected among CTC partici-
pants, 129 (31.6%) were at least 10 mm in size, 110 (30%) had
a villous component >20% and 37 (9.1%) contained high-grade
dysplasia. Advanced and non-advanced FS adenomas were
mostly sessile and left sided; CTC non-advanced adenomas
were mostly sessile and right sided, whereas CTC advanced
adenomas were sessile or pedunculated and almost equally
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distributed in the left and right colon. Additional information
on polyp morphology and distribution is available in the online
supplementary appendix (table S1).
ECFs and adverse events
Clinically relevant ECFs (CT colonography reporting and data
system (C-RADS) E4 and aortic aneurysms ≥4 cm) were diag-
nosed in 35 (1.2%) CTC participants, of whom 29 (1.0%) had
a new diagnosis that required further assessment. Further details
on ECFs are provided in the online supplementary appendix.
In the CTC group, 14 (0.5%) patients complained of a vago-
vagal reaction and one (0.04%) a cutaneous rash. In the FS
group, vago-vagal reactions occurred in 9 (0.4%) patients. In
both groups, adverse events resolved spontaneously and did not
require medical treatment or hospital admission.
DISCUSSION
According to this study, the performance of CTC and FS when
used as primary screening tests in a population-based setting is
comparable, both in terms of participation and AN detection.
Equivalent participation rates could be related to the similar
perceived burden of the two tests, in that both do not necessitate
sedation and cathartic preparation. Contrary to what was
expected, the offer of a less-invasive radiologic examination
apparently did not enhance participation. However, even if the
study was not powered to detect such difference as statistically
significant, a 3.4% absolute increase in screening uptake may
result in a substantial additional impact of the programme at the
population level. Of note, adherence to FS screening in our
study was similar to the average attendance in the local screen-
ing programme,6 19 suggesting that the population enrolled in
this study is representative of the population complying with the
screening invitation. The COCOS trial11 showed a higher CTC
uptake, but participation rate in CRC screening trials with FS
and FIT in The Netherlands is also higher, suggesting a greater
awareness of cancer prevention in the Dutch population.11 20
The finding of a differential uptake by gender with the two
tests deserves consideration. Reports from the Piedmont screen-
ing program6 19 consistently showed higher participation in FS
screening among men than among women whereas no such
trend was observed in this study. A 30% increase in screening
uptake was instead observed among men invited for CTC com-
pared with those invited for FS. A higher screening uptake
among men may enhance the health impact of screening, since
men have a higher AN prevalence compared with women.
However, measures to reduce the gender gap in screening cover-
age also need to be implemented when using CTC, as is already
the case with FS.19
The lack of superiority of CTC compared with FS in terms of
AN detection was at least in part unexpected. Similar to
Figure 1 Flow diagram of the two randomized clinical trials (RCTs) comparing participation and advanced neoplasia detection of CT colonography
(CTC) and flexible sigmoidoscopy (FS).
Table 1 Detection trial: patient characteristics
Sigmoidoscopy CT colonography Total
Age (years)
Mean (SD) 58.6 (1.08) 58.6 (1.09) 58.6 (1.08)
Gender, N (%)
Male 1375 (51.4) 1329 (51.2) 2704 (51.3)
Female 1298 (48.6) 1266 (48.8) 2564 (48.7)
Family risk*, N (%)
No 2444 (92.1) 2309 (90.9) 4753 (86.0)
Yes 209 (7.9) 230 (9.1) 439 (8.5)
Previous colonoscopy†, N (%)
No 2324 (94.1) 2266 (91.6) 4590 (87.2)
Yes 344 (12.9) 328 (12.6) 672 (12,8)
*Information was missing in 56 CTC cases and in 20 FS cases.
†Information was missing in 1 CTC case and in 5 FS cases.
FS, flexible sigmoidoscopy.
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colonoscopy, CTC has the advantage of a systematic assessment
of the proximal colon. Indeed, the DR of CTC for proximal AN
was twofold higher than with FS. The finding of a similar preva-
lence of proximal AN at CTC as at colonoscopy screening in a
comparable target population enrolled in the SCORE 3 trial19
would suggest that colonoscopy and CTC may have comparable
sensitivity in detecting proximal AN. Of note, about 80% of
subjects with proximal AN (including three CRCs) did not have
‘high-risk’ distal lesions and they would not have been diag-
nosed with FS screening.
In contrast with previous comparative studies, the DR of
distal AN was substantially lower with CTC than with FS.7 8 11
There could be several contributing factors for this that warrant
further investigation. First, the non-cathartic preparation
scheme and the tagging regimen adopted in this study might
have affected exam quality, particularly of the distal colon.
Second, the distal colon is more rigid than the proximal colon
and is the favoured site of diverticular disease, and this may
result in a suboptimal distension when insufflating CO2. Third,
particularly in the above reported adverse conditions, adopting
a new reading algorithm with CAD as the first reader might
have negatively affected CTC interpretation. Being a highly
technological test and a newcomer, CTC has the potential to
improve its performances.
Two additional variables of CTC must be considered in the
setting of population-based screening programmes, namely
ECFs and radiation exposure. The adoption of strict criteria to
refer people with ECFs to clinical assessments in our study
resulted in a very low rate of referrals. Still, in programmes tar-
geting asymptomatic subjects, in the absence of strong evidence
supporting the effectiveness of assessing and treating ECFs, the
choices concerning ECF management may have a critical impact
on the cost-effectiveness profile of the test.
Table 2 Per-patient findings by gender for sigmoidoscopy and CT colonography (CTC)
Flexible sigmoidoscopy CTC
Women
N=1298
%
(95% CI)
Men
N=1375
%
(95% CI)
Total
N=2673
%
(95% CI)
Women
N=1266
%
(95% CI)
Men
N=1329
%
(95% CI)
Total
N=2595
%
(95% CI)
RR*
(95% CI)
No finding 1087
83.8
(81.6 to 85.7)
1018
74.0
(71.6 to 76.3)
2105
78.8
(77.1 to 80.3)
1183
93.4
(91.8 to 94.7)
1183
89.0
(87.2 to 90.6)
2366
91.2
(90.0 to 92.2)
–
Non-neoplastic polyp† 82
6.3
(5.5 to 7.8)
143
10.4
(8.8 to 12.1)
225
8.4
(7.4 to 9.5)
12
0.9
(0.5 to 1.6)
12
0.9
(0.5 to 1.6)
24
0.9
(5.9 to 1.4)
0.42
(0.36 to 0.48)
Non-advanced adenoma 86
6.6
(5.3 to 8.1)
130
9.5
(8.0 to 11.1)
216
8.1
(7.0 to 9.2)
29
2.3
(1.9 to 3.3)
43
3.2
(2.4 to 4.3)
72
2.8
(2.0 to 3.5)
0.76
(0.65 to 0.89)
Advanced adenoma of any size 41
3.2
(2.3 to 4.3)
77
5.6
(4.4 to 6.9)
118
4.4
(3.7 to 5.3)
37
2.9
(2.0 to 4.0)
86
6.5
(5.2 to 7.9)
123
4.7
(4.0 to 5.6)
1.07
(0.84 to 1.37)
Advanced adenoma
<6 mm
6
0.46
(0.2 to 1.0)
6
0.44
(0.2 to 0.9)
12
0.45
(0.2 to 0.8)
0
0.0
(0.0 to 0.3)
3
0.23
(0.05 to 0.7)
3
0.12
(0.02 to 0.3)
–
Advanced adenoma
6–9 mm
4
0.31
(0.08 to 0.8)
6
0.44
(0.2 to 0.9)
10
0.37
(0.02 to 0.68)
7
0.55
(0.20 to 1.00)
15
1.1
(0.6 to 1.8)
22
0.9
(0.5 to 1.3)
–
Advanced adenoma
≥6 mm
35
2.4
(1.6 to 3.4)
70
4.7
(3.6 to 5.9)
105
3.6
(2.9 to 4.3)
37
2.4
(1.6 to 3.4)
83
5.1
(4.0 to 6.4)
120
3.8
(3.8 to 4.6)
1.17
(0.91 to 1.52)
Advanced adenoma
≥10 mm
31
2.4
(1.6 to 3.4)
64
4.7
(3.6 to 5.9)
95
3.6
(2.9 to 4.3)
30
2.4
(1.6 to 3.4)
68
5.1
(4.0 to 6.4)
98
3.8
(3.8 to 4.6)
1.06
(0.81 to 1.40)
Colorectal cancer§ 2
0.2
(0.02 to 0.6)
7
0.5
(0.02 to 1.00)
9
0.3
(0.02 to 0.6)
5
0.4
(0.1 to 0.9)
5
0.4
(0.1 to 0.9)
10
0.4
(0.2 to 0.7)
1.14
(0.47 to 2.31)
*Crude RR (relative risk), experimental (CTC) versus control (FS) group.
†Normal, hyperplastic or inflammatory.
§FS arm—UICC stage I, n=3; II, n=2; III, n=3; IV, n=1.
CTC arm—UICC stage I, n=3; II, n=5; III, n=2.
FS, flexible sigmoidoscopy; UICC, Union for International Cancer Control.
Table 3 Factors associated with advanced neoplasia detection at
multivariate analysis
RR* 95% CI
Gender
Women 1
Men 1.94 1.50 to 2.51
1 FDR with colorectal cancer
No 1
Yes 1.30 0.87 to 1.95
Performed previous TC
No 1
Yes 0.61 0.39 to 0.96
Screening test
Sigmoidoscopy 1
CT colonography 1.05 0.84 to 1.35
*RR adjusted for screening centre and for all other variables in the model.
FDR, first-degree relative; RR, relative risk; TC, colonoscopy.
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Similarly the possible impact of radiation exposure of a large
number of asymptomatic subjects is unknown and potentially
harmful, even when low-dose scanning protocols are applied.
In the detection trial we adopted a two-stage recruitment pro-
cedure to ensure comparability between screening arms, by
reducing a potential source of variability related to self-selection
of subjects with different baseline characteristics and CRC risk
in the two arms. The finding of a higher participation rate
among men (showing a higher AN prevalence) in the CTC arm
in the participation trial would indicate that self-selection could
indeed bias the estimate of the relative DR. Restricting enrol-
ment to volunteers enhanced the validity of the comparison
between the screening methods, although it could limit the gen-
eralisability of the study findings. However, a recent analysis21
comparing subjects who volunteered in the SCORE trial, which
targeted a similar population, with those who did not respond
Table 4 Distribution of recto-sigmoid and proximal advanced neoplasia among flexible sigmoidoscopy (FS) and CT colonography (CTC)
screenees
Sigmoidoscopy, N
% (95% CI)
CTC, N
% (95% CI)
RR*
(95% CI)
Distal colon
Women (1298 FS; 1266 CTC) 36
2.8 (1.9 to 3.8)
23
1.8 (1.2 to 2.7)
0.66 (0.40 to 1.10)
Men (1375 FS; 1329 CTC) 73
5.3 (4.3 to 6.6)
53
4.0 (3.0 to 5.2)
0.76 (0.53 to 1.08)
Total 109
4.1 (3.3 to 4.9)
76
2.9 (2.3 to 3.7)
0.72 (0.54 to 0.96)
Proximal colon†
Women (1298 FS; 1266 CTC) 13
1.0 (0.5 to 1.7)
21
1.7 (1.0 to 2.5)
1.66 (0.83 to 3.27)
Men (1375 FS; 1329 CTC) 21
1.5 (0.9 to 2.3)
48
3.6 (2.7 to 4.8)
2.3 (1.4 to 3.8)
Total 34‡
1.3 (0.9 to 1.8)
69‡
2.7 (2.1 to 3.4)
2.06 (1.37 to 3.10)
*Crude RR (relative risk), experimental (CTC) versus control (FS) group.
†Proximal is defined as descending colon, transverse colon, ascending colon, or caecum.
‡Including 16 (47.1%) FS and 12 (17.3%) CTC cases who had synchronous advanced neoplasia in the distal colon.
Table 5 Histological characteristics of advanced neoplasia detected by CT colonography (CTC) and flexible sigmoidoscopy (FS) according to size
Sigmoidoscopy, N
(%; 95% CI)
CTC, N
(%; 95% CI)
RR
(95% CI)
Lesion size ≥10 mm, n 117 129
TV or villous 54 (46.2; 36.9 to 55.6) 70 (54.3; 45.7 to 63.1) 1.2 (0.9 to 1.5)
High-grade dysplasia 26 (22.2; 15.1 to 30.6) 16 (12.4; 7.3 to 19.4)
Tubular 56 (47.9; 38.5 to 57.3) 46 (35.7; 27.6 to 44.6) 0.8 (0.6 to 1.0)
High-grade dysplasia 4 (3.4; 0.9 to 8.5) 2 (1.6; 0.2 to 5.5)
SSA/P—TSA 7 (5.1; 2.4 to 1.2) 13 (10.1; 5.5 to 16.6) 1.7 (0.9 to 4.1)
High-grade dysplasia 0 (0.0; 0.0 to 3.1) 2 (1.6; 0.2 to 5.5)
Lesion size 6–9 mm, n 138 153
TV or villous 19 (13.8; 8.5 to 20.7) 32 (20.9; 14.8 to 28.2) 1.5 (0.9 to 2.6)
High-grade dysplasia 1 (1.1; 0.02 to 4.0) 7 (4.6; 1.9 to 9.2)
Tubular 113 (81.9; 74.4 to 87.9) 109 (71.2; 63.4 to 78.3) 0.9 (0.8 to 1.0)
High-grade dysplasia 1 (0.7; 0.02 to 4.0) 7 (4.6; 1.8 to 9.2)
SSA/P—TSA 6 (4.3; 1.6 to 9.2) 12 (7.8; 4.2 to 13.3) 2.1 (0.8 to 5.5)
High-grade dysplasia 0 (0.0) 0 (0.0) –
Lesions size <5 mm, n 305 126
TV or villous 15 (4.9; 2.8 to 8.0) 8 (6.3; 2.8 to 12.1) 1.3 (0.6 to 3.0)
High-grade dysplasia 1 (0.4; 0 to 1.8) 2 (1.6; 0.2 to 5.6)
Tubular 273 (89.5; 85.5 to 92.7) 107 (84.9; 77.5 to 90.7) 1.3 (0.8 to 2.3)
High-grade dysplasia 4 (1.3; 0.4 to 3.3) 3 (2.4; 0.5 to 6.8)
SSA/P—TSA 17 (5.6) 11 (8.7) 1.6 (0.8 to 3.2)
High-grade dysplasia 0 (0.0) 0 (0.0)
Overall 560 408
Total number of advanced adenomas* 156 (27.9; 24.2 to 31.8) 179 (43.9; 39.0 to 48.8) 1.6 (1.3 to 1.9)
Total number of non-advanced lesions 404 (72.1; 68.2 to 75.8) 229 (56.1; 51.2 to 61.0)
*Including serrated polyps ≥10 mm, or with high-grade dysplasia.
SSA/P, small sessile serrated adenoma/polyp; TSA, traditional serrated adenoma; TV, tubulovillous.
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to the recruitment questionnaire showed that volunteers had
lower CRC mortality, but the same CRC incidence as non-
responders, suggesting that our enrolment procedure is unlikely
to influence the main outcome of the trial. It should be consid-
ered that the effectiveness of the two approaches in population
screening settings not only depends on the relative DR but it
results from the combination of participation and DR, the
former being more strictly influenced by local conditions.
In conclusion, in a population-based screening trial, CTC
showed a similar AN detection and acceptability as FS.
Comparative cost-effectiveness data are needed to assess the pos-
sible role of CTC in this setting.
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